| . | TWILIGHT, N Engl J Med 2019 . | STOPDAPT-2, JAMA 2019 . | SMART-CHOICE, JAMA 2019 . | GLOBAL LEADERS, Lancet 2018 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (Cis) . | S-DAPT . | DAPT . | HR (CIs) . | |
| MACCE (all cause of death, myocardial infarction, and stroke; %) | 3.9 | 3.9 | 0.99 (0.78–1.25) | 2.80 | 2.97 | NA | 2.9 | 2.5 | 0.4 (−∞ to 1.3)a | 2.47 | 2.98 | 0·83 (0·69–1·00) |
| Death from any cause (%) | 1.00 | 1.30 | 0.75 (0.48–1.18) | 1.42 | 1.21 | 1.18 (0.63–2.21) | 1.40 | 1.20 | 1.18 (0.63–2.21) | 1.35 | 1.64 | 0.82 (0.64–1.06) |
| MI (%) | 2.70 | 2.70 | 1.00 (0.75–1.33) | 0.88 | 0.75 | 1.19 (0.54–2.67) | 0.80 | 1.20 | 0.66 (0.31–1.40) | 2.24 | 1.98 | 1.14 (0.92–1.41) |
| Stroke (ischaemic or haemorrhagic) (%) | 0.50 | 0.20 | 2.00 (0.86–4.67) | 0.54 | 1.09 | 0.50 (0.22–1.18) | 0.80 | 0.30 | 2.23 (0.78–6.43) | 0.65 | 0.61 | 1.07 (0.72–1.57) |
| Stent thrombosis (definite or probable; %) | 0.40 | 0.60 | 0.74 (0.37–1.47) | 0.27 | 0.07 | 4.03 (0.45–36.08) | 0.20 | 0.10 | 1.51 (0.25–9.02) | 0.66 | 0.51 | 1.30 (0.86–1.95) |
| BARC type 3 or 5 (%) | 1.00 | 2.00 | 0.49 (0.33–0.74) | 0.54 | 1.81 | 0.30 (0.13–0.65) | 0.80 | 1.00 | 0.87 (0.40–1.88) | 1.47 | 1.70 | 0.86 (0.67–1.11) |
| . | TWILIGHT, N Engl J Med 2019 . | STOPDAPT-2, JAMA 2019 . | SMART-CHOICE, JAMA 2019 . | GLOBAL LEADERS, Lancet 2018 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (Cis) . | S-DAPT . | DAPT . | HR (CIs) . | |
| MACCE (all cause of death, myocardial infarction, and stroke; %) | 3.9 | 3.9 | 0.99 (0.78–1.25) | 2.80 | 2.97 | NA | 2.9 | 2.5 | 0.4 (−∞ to 1.3)a | 2.47 | 2.98 | 0·83 (0·69–1·00) |
| Death from any cause (%) | 1.00 | 1.30 | 0.75 (0.48–1.18) | 1.42 | 1.21 | 1.18 (0.63–2.21) | 1.40 | 1.20 | 1.18 (0.63–2.21) | 1.35 | 1.64 | 0.82 (0.64–1.06) |
| MI (%) | 2.70 | 2.70 | 1.00 (0.75–1.33) | 0.88 | 0.75 | 1.19 (0.54–2.67) | 0.80 | 1.20 | 0.66 (0.31–1.40) | 2.24 | 1.98 | 1.14 (0.92–1.41) |
| Stroke (ischaemic or haemorrhagic) (%) | 0.50 | 0.20 | 2.00 (0.86–4.67) | 0.54 | 1.09 | 0.50 (0.22–1.18) | 0.80 | 0.30 | 2.23 (0.78–6.43) | 0.65 | 0.61 | 1.07 (0.72–1.57) |
| Stent thrombosis (definite or probable; %) | 0.40 | 0.60 | 0.74 (0.37–1.47) | 0.27 | 0.07 | 4.03 (0.45–36.08) | 0.20 | 0.10 | 1.51 (0.25–9.02) | 0.66 | 0.51 | 1.30 (0.86–1.95) |
| BARC type 3 or 5 (%) | 1.00 | 2.00 | 0.49 (0.33–0.74) | 0.54 | 1.81 | 0.30 (0.13–0.65) | 0.80 | 1.00 | 0.87 (0.40–1.88) | 1.47 | 1.70 | 0.86 (0.67–1.11) |
Estimate of difference, % (95% one-sided CI). NA, not available.
| . | TWILIGHT, N Engl J Med 2019 . | STOPDAPT-2, JAMA 2019 . | SMART-CHOICE, JAMA 2019 . | GLOBAL LEADERS, Lancet 2018 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (Cis) . | S-DAPT . | DAPT . | HR (CIs) . | |
| MACCE (all cause of death, myocardial infarction, and stroke; %) | 3.9 | 3.9 | 0.99 (0.78–1.25) | 2.80 | 2.97 | NA | 2.9 | 2.5 | 0.4 (−∞ to 1.3)a | 2.47 | 2.98 | 0·83 (0·69–1·00) |
| Death from any cause (%) | 1.00 | 1.30 | 0.75 (0.48–1.18) | 1.42 | 1.21 | 1.18 (0.63–2.21) | 1.40 | 1.20 | 1.18 (0.63–2.21) | 1.35 | 1.64 | 0.82 (0.64–1.06) |
| MI (%) | 2.70 | 2.70 | 1.00 (0.75–1.33) | 0.88 | 0.75 | 1.19 (0.54–2.67) | 0.80 | 1.20 | 0.66 (0.31–1.40) | 2.24 | 1.98 | 1.14 (0.92–1.41) |
| Stroke (ischaemic or haemorrhagic) (%) | 0.50 | 0.20 | 2.00 (0.86–4.67) | 0.54 | 1.09 | 0.50 (0.22–1.18) | 0.80 | 0.30 | 2.23 (0.78–6.43) | 0.65 | 0.61 | 1.07 (0.72–1.57) |
| Stent thrombosis (definite or probable; %) | 0.40 | 0.60 | 0.74 (0.37–1.47) | 0.27 | 0.07 | 4.03 (0.45–36.08) | 0.20 | 0.10 | 1.51 (0.25–9.02) | 0.66 | 0.51 | 1.30 (0.86–1.95) |
| BARC type 3 or 5 (%) | 1.00 | 2.00 | 0.49 (0.33–0.74) | 0.54 | 1.81 | 0.30 (0.13–0.65) | 0.80 | 1.00 | 0.87 (0.40–1.88) | 1.47 | 1.70 | 0.86 (0.67–1.11) |
| . | TWILIGHT, N Engl J Med 2019 . | STOPDAPT-2, JAMA 2019 . | SMART-CHOICE, JAMA 2019 . | GLOBAL LEADERS, Lancet 2018 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (CIs) . | S-DAPT . | DAPT . | HR (Cis) . | S-DAPT . | DAPT . | HR (CIs) . | |
| MACCE (all cause of death, myocardial infarction, and stroke; %) | 3.9 | 3.9 | 0.99 (0.78–1.25) | 2.80 | 2.97 | NA | 2.9 | 2.5 | 0.4 (−∞ to 1.3)a | 2.47 | 2.98 | 0·83 (0·69–1·00) |
| Death from any cause (%) | 1.00 | 1.30 | 0.75 (0.48–1.18) | 1.42 | 1.21 | 1.18 (0.63–2.21) | 1.40 | 1.20 | 1.18 (0.63–2.21) | 1.35 | 1.64 | 0.82 (0.64–1.06) |
| MI (%) | 2.70 | 2.70 | 1.00 (0.75–1.33) | 0.88 | 0.75 | 1.19 (0.54–2.67) | 0.80 | 1.20 | 0.66 (0.31–1.40) | 2.24 | 1.98 | 1.14 (0.92–1.41) |
| Stroke (ischaemic or haemorrhagic) (%) | 0.50 | 0.20 | 2.00 (0.86–4.67) | 0.54 | 1.09 | 0.50 (0.22–1.18) | 0.80 | 0.30 | 2.23 (0.78–6.43) | 0.65 | 0.61 | 1.07 (0.72–1.57) |
| Stent thrombosis (definite or probable; %) | 0.40 | 0.60 | 0.74 (0.37–1.47) | 0.27 | 0.07 | 4.03 (0.45–36.08) | 0.20 | 0.10 | 1.51 (0.25–9.02) | 0.66 | 0.51 | 1.30 (0.86–1.95) |
| BARC type 3 or 5 (%) | 1.00 | 2.00 | 0.49 (0.33–0.74) | 0.54 | 1.81 | 0.30 (0.13–0.65) | 0.80 | 1.00 | 0.87 (0.40–1.88) | 1.47 | 1.70 | 0.86 (0.67–1.11) |
Estimate of difference, % (95% one-sided CI). NA, not available.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
